Home › NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

Dec 06, 2016

NEW YORK (GenomeWeb) – NantHealth announced today that it has signed an exclusive reseller agreement with Teva Pharmaceuticals subsidiary Oncotest-Teva to distribute its GPS Cancer molecular test in Israel.

Under the terms of the deal, Oncotest-Teva will be the only distributor of GPS Cancer to clinicians in that country. Further terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

What's Popular?

In Cancer

  1. AstraZeneca Publishes Head-to-Head Study of 13 KRAS Mutation Detection Technologies

    Premium

  2. FDA Accepts Myriad BRACAnalysis CDx Supplementary PMA for Lynparza in Breast Cancer Indication

  3. Thermo Fisher's NSCLC Companion Dx Covered by Regence BCBS

  4. At FDA/AACR Liquid Biopsy Meeting, Researchers Detail Concordance Challenges, Standards

    Premium

  5. NIH to Fund Cancer MDx Development Projects

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.